Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.4% – Here’s What Happened

Rapport Therapeutics, Inc. (NASDAQ:RAPP)’s stock price dropped 7.4% on Wednesday. The company traded as low as $27.82 and last traded at $27.2110. Approximately 121,229 shares changed hands during trading, a decline of 69% from the average daily volume of 391,842 shares. The stock had previously closed at $29.37.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Rapport reported that its Phase 2 trial of RAP-219 met both the primary and secondary endpoints. At Week 3, the treatment produced a statistically significant placebo-adjusted 3.1-point improvement in the Young Mania Rating Scale and a 0.4-point improvement in the Clinical Global Impression–Bipolar severity score. Rapport Phase 2 topline results
• Positive Sentiment: The company plans to advance RAP-219 into Phase 3 bipolar-mania trials, reducing some development uncertainty and supporting the potential for a larger commercial opportunity. Rapport plans Phase III trials
• Positive Sentiment: Analysts responded favorably: BTIG raised its price target to $89 from $75, Raymond James increased its target to $86 from $75, and HC Wainwright reaffirmed a Buy rating with a $66 target. Analysts have cited a potential blockbuster opportunity, with estimated peak sales near $1 billion. Raymond James price target increase
• Neutral Sentiment: Investor reaction has been volatile, with unusually heavy trading volume following the data release as the market weighs the clinical results and the transition toward Phase 3. Rapport trading volume
• Negative Sentiment: Some coverage characterized the trial win as modest because RAP-219 fell short of the study’s original ambitions, which may explain profit-taking and the stock’s continued weakness despite positive headline results. Rapport Phase 2 analysis

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BTIG Research boosted their price objective on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Guggenheim lifted their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Rapport Therapeutics in a report on Tuesday. Finally, Raymond James Financial restated a “strong-buy” rating and set a $86.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $67.00.

Rapport Therapeutics Stock Down 10.8%

The firm’s 50 day moving average price is $40.31 and its two-hundred day moving average price is $39.13. The firm has a market capitalization of $1.26 billion, a PE ratio of -8.62 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Abraham Ceesay sold 1,147 shares of the company’s stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $30.66, for a total transaction of $35,167.02. Following the completion of the transaction, the chief executive officer directly owned 452,245 shares in the company, valued at $13,865,831.70. This represents a 0.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Cheryl Gault sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total transaction of $331,900.00. Following the transaction, the chief operating officer owned 139,914 shares of the company’s stock, valued at $4,643,745.66. This represents a 6.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 97,976 shares of company stock worth $4,420,349 over the last quarter. Insiders own 12.48% of the company’s stock.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently modified their holdings of the company. Algert Global LLC acquired a new position in Rapport Therapeutics during the 2nd quarter valued at about $9,327,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $74,360,823. Legal & General Group Plc acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $940,000. Walleye Capital LLC bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $4,257,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $3,426,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.